RUC. Repositorio da Universidade da Coruña
Publicación
Artículo científico (JournalArticle)
Activity of imipenem-relebactam against a large collection of pseudomonas aeruginosa clinical isolates and isogenic β-lactam-resistant mutants
[Abstract] Imipenem and imipenem-relebactam MICs were determined for 1,445 Pseudomonas aeruginosa clinical isolates and a large panel of isogenic mutants showing the most relevant mutation-driven β-lactam resistance mechanisms. Imipenem-relebactam showed the highest susceptibility rate (97.3%), followed by colistin and ceftolozane-tazobactam (both 94.6%). Imipenem-relebactam MICs remained ≤2 μg/ml in all 16 isogenic PAO1 mutants and in 8 pairs of extensively drug-resistant clinical strains that had developed resistance to ceftolozane-tazobactam and ceftazidime-avibactam due to mutations in OXA-10 or AmpC., The work was supported by MSD and by Plan Nacional de I+D+i 2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016), and grant PI18/00076 cofinanced by European Regional Development Fund (ERDF) “A way to achieve Europe,” Operative Program Intelligent Growth 2014–2020. The work was partially financed by MSD through Investigator Initiated Studies Program to A.O.